Results 141 to 150 of about 4,006,149 (207)

Resolving Endoplasmic Reticulum‐Protein Misfolding Restores Corticosteroid Sensitivity in Experimental Models of Severe Asthma

Allergy, Volume 81, Issue 9, Page 3221-3235, September 2026.
This study investigates the role of ER stress in steroid resistance in severe asthma. Results from advanced 3D models of human bronchial epithelial cells, steroid‐resistant severe asthma mouse models, and human severe asthma sputum samples show that treatment with ICS in combination with the ER stress inhibitor 4‐PBA significantly enhances steroid ...
Prabuddha S. Pathinayake, Alexandra C. Brown, Nikhil T. Awatade, Philip M. Hansbro, Katherine J. Baines, Richard Y. Kim, Nathan W. Bartlett, Jay C. Horvat, Peter A. B. Wark   +8 more
wiley   +1 more source

Photocatalytic Synthesis of Penem-type Pseudo-Natural Products Delivers a Novel Apo-IDO1 Inhibitor Chemotype

The synthesis of pseudo-natural products (PNPs) by combining biosynthetically unrelated fragments provides a powerful strategy for exploring uncharted biological and chemical spaces.
Yue-Hui Xing, Guan-Zhou Yang, Jian-Min Yue, Wen-Jing Gao   +3 more
core   +1 more source

The Airway Transcriptome in Type 2 Cytokine Biomarker‐High and ‐Low Severe Asthma

Allergy, Volume 81, Issue 9, Page 3300-3317, September 2026.
This study distinguishes severe asthma–related airway transcriptomic changes from the effects of high‐dose ICS. Most dysregulated genes in severe asthma show concordance with corticosteroid responses. Corticosteroid‐resistant T2‐high asthma featured T2‐high and epithelial barrier gene upregulation, while T2‐low asthma featured Th1/IL‐17 signatures. ASM,
Jiashu Shen, Rekha Chaudhuri, Stephen Bicknell, Adel H. Mansur, Rahul Shrimanker, Ian D. Pavord, Stephen J. Fowler, Vanessa Brown, Lorcan P. McGarvey, Peter H. Howarth, Sven‐Erik Dahlén, Ian M. Adcock, Nazanin Zounemat‐Kermani, Joseph R. Arron, Liam G. Heaney, David F. Choy, Timothy S. C. Hinks, Emanuele Marchi, Peter Bradding, on behalf of the UK Medical Research Council Refractory Asthma Stratification programme (RASP‐UK)   +19 more
wiley   +1 more source

GCN2 in proteostasis: structural logic, signalling networks and disease

The FEBS Journal, Volume 293, Issue 18, Page 5627-5644, September 2026.
Threats to protein synthesis activate the kinase GCN2, initiating the integrated stress response (ISR). GCN2 is triggered by stalled ribosomes and uncharged tRNAs, which accumulate when amino acids are scarce. The ISR adjusts cellular physiology by promoting redox balance, protein quality control, and mitochondrial optimisation.
JiaYi Zhu, Stefan J. Marciniak
wiley   +1 more source

Image_1_Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.jpeg

The tryptophan-degrading enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a plastic immune checkpoint molecule that potently orchestrates immune responses within the tumor microenvironment (TME).
Maria Laura Belladonna (8895800), Maria Teresa Pallotta (8564109), Chiara Suvieri (17843111), Eleonora Panfili (7280225), Ciriana Orabona (131940), Sofia Rossini (17843108), Claudia Volpi (7280219), Giada Mondanelli (7280207), Sara Ambrosino (8482485), Antonio Macchiarulo (182335)   +9 more
core   +1 more source

Image_2_Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.jpeg

The tryptophan-degrading enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a plastic immune checkpoint molecule that potently orchestrates immune responses within the tumor microenvironment (TME).
Maria Laura Belladonna (8895800), Maria Teresa Pallotta (8564109), Chiara Suvieri (17843111), Eleonora Panfili (7280225), Ciriana Orabona (131940), Sofia Rossini (17843108), Claudia Volpi (7280219), Giada Mondanelli (7280207), Sara Ambrosino (8482485), Antonio Macchiarulo (182335)   +9 more
core   +1 more source

Discovery of a novel miconazole analogue as a dual apo-IDO1 inhibitor and ABCB1 modulator for cancer immunotherapy and chemosensitizing

Indoleamine 2,3-dioxygenase 1 (IDO1) facilitates tumoral immune evasion via the kynurenine (Kyn) pathway, while ABCB1-mediated efflux drives multidrug resistance.
Özdemir, Zeynep, Chen, Pin-Chen, Chang, Yung-Chieh, Tseng, Kai-Yu, Lin, Kai-Hsuan, Ho, Yun-Yun, Reynisson, Jóhannes, Cheung, Chun Hei Antonio, Sari, Suat, Leung, Euphemia   +9 more
core   +1 more source

Inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) for cancer therapy

, 2015
Immune escape is a central hallmark of cancer. A tryptophan-catabolising enzyme indoleamine 2,3-dioxygenase-1 (IDO1) is a dominant immune escape mechanism in a broad range of human tumours and its expression is associated with a poor prognosis in cancer.
Tomek, Petr
core  

IDO1 Inhibitor MK-7162

Definitions, 2020

semanticscholar   +1 more source

Compensatory pathways in tryptophan metabolism and immune regulation following IDO inhibition. [PDF]

Mol Biol Rep
Gontijo I, Camurça M, Kfoury JR.
europepmc   +1 more source